BOBULSKY SUSAN sold $60K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,875 shares of Adaptive Biotechnologies Corp (ADPT) at $32.00 on 2026-11-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Nov 14, 2026, 12:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
high confidence
Mentioned
$ADPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

Small insider sale unlikely to move price materially but may be noted by quantitative traders.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate developments not disclosed.

Relevance 2/10Novelty 2/10Timing: filing date 2026‑11‑13, relevant today

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$ADPTBearishHigh confidence
Context

Form 4 shows Chief Commercial Officer Susan Bobulsky sold 1,875 shares for $60,000 via a 10b5‑1 plan.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to holdings and executed under a pre‑arranged plan, so impact is limited but could cause minor downside bias.

Market effects

Minimal effect on biotech sector; typical insider sales are routine.

None

None

Counterpoint

Sale could be unrelated to fundamentals; investors may ignore.

Key entities

  • Adaptive Biotechnologies Corp

    NASDAQ‑listed biotech firm.

  • Susan Bobulsky

    Chief Commercial Officer, MRD.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.